Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors

Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors

Abstract Precision medicine based on cancer genomics is being applied in clinical practice. However, patients do not always derive benefits from genomic testing. Here, we performed targeted amplicon exome sequencing‐based panel tests, including 160 cancer‐related genes (PleSSision‐160), on 88 malign...

Full description

Bibliographic Details
Main Authors: Keiko Saotome, Tatsuyuki Chiyoda, Eriko Aimono, Kohei Nakamura, Shigeki Tanishima, Sachio Nohara, Chihiro Okada, Hideyuki Hayashi, Yuka Kuroda, Hiroyuki Nomura, Nobuyuki Susumu, Takashi Iwata, Wataru Yamagami, Fumio Kataoka, Hiroshi Nishihara, Daisuke Aoki
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Cancer Medicine
Subjects:
Actionable gene alteration
Clinical sequencing
Druggable gene alteration
Ovarian cancer
Precision medicine
Online Access:https://doi.org/10.1002/cam4.3383

Internet

https://doi.org/10.1002/cam4.3383

Similar Items